GSK secured FDA approval for Jideytro, known scientifically as zidesamtinib, marking the British pharmaceutical giant’s first-ever commercial lung cancer treatment.
The approval came roughly two months ahead of the FDA’s original target decision date of September 18, representing an unusually swift regulatory outcome for the company.
The milestone was made possible by GSK’s $10.6 billion acquisition of Nuvalent, with the green light arriving just one week after the deal formally closed.
Jideytro is approved to treat adult patients with advanced ROS1-positive non-small cell lung cancer who have previously received a ROS1 inhibitor.
GSK’s chief scientific officer Tony Wood said: “The rapid progression of Jideytro from development to approval reflects both the strength of the underlying science and the urgent need for additional effective and tolerable treatments for ROS1-positive lung cancer.”
The current label restricts Jideytro to second-line use, but GSK has confirmed it intends to seek a first-line label expansion, building on prior comments made by Nuvalent before the acquisition closed.
At the 2026 American Society of Clinical Oncology annual meeting, Nuvalent presented preliminary data showing zidesamtinib achieved a 40% overall response rate across 10 tumour types beyond NSCLC.
Those results indicate that Jideytro may carry pan-tumour potential, significantly broadening the commercial case for the drug beyond its initial approved indication.
GSK faces meaningful competition in the ROS1-positive NSCLC market, most notably from Ibtrozi, developed by Nuvation Bio, which received a line-agnostic FDA approval in June 2025 and generated $18.5 million in the first quarter of 2026.
Ibtrozi also features intracranial activity and TRK sparing, positioning it as a direct rival to Jideytro across multiple treatment settings and patient profiles.
GSK has described Jideytro as having “multi-blockbuster potential,” a significant claim given that no existing ROS1 NSCLC drug from Pfizer, Roche, or Bristol Myers Squibb has approached that threshold.
Nuvalent designed Jideytro to overcome treatment-emergent ROS1 mutations while sparing the structurally related TRK family, reducing the risk of off-target toxicities that have troubled earlier therapies.
The drug also features strong central nervous system penetration, addressing brain metastases, which represent a common and serious complication in ROS1-positive non-small cell lung cancer patients.
GSK is advancing further assets from the Nuvalent pipeline, including neladalkib for ALK-altered NSCLC, which is currently under FDA review with a target decision date of 27 November 2026.